Statin-induced myopathy: minimize the risk and manage according to symptoms and creatine kinase levels

Author：

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.26, Iss.10, 2010-10, pp. : 21-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SLCO1B1 variants and increased risk of statin-induced myopathy

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Statin-induced myopathy: a review and update

By Abd Thura T Jacobson Terry A

Expert Opinion on Drug Safety, Vol. 10, Iss. 3, 2011-05 ,pp. : 373-387

Informa Healthcare

Access to resources Recommend Favorite

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment

By Chatzizisis Yiannis S. Koskinas Konstantinos C.

Drug Safety, Vol. 33, Iss. 3, 2010-03 ,pp. : 171-187

Adis International

Access to resources Recommend Favorite

Statin-induced liver disease a "myth"

Reactions Weekly, Vol. 1, Iss. 1330, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Daptomycin: Elevated creatine kinase levels: case report

Reactions Weekly, Vol. 1, Iss. 1343, 2011-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite